Related Experiment Videos
LPI-labile plasma iron in iron overload
Z Ioav Cabantchik1, William Breuer, G Zanninelli
1Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, 91904 Israel. ioav@cc.huji.ac.il
Best Practice & Research. Clinical Haematology
|March 2, 2005
Summary
Labile plasma iron (LPI), a harmful iron component, can cause organ damage in iron overload. Iron chelation therapy effectively reduces LPI exposure in thalassemia patients.
Area of Science:
- Hematology
- Clinical Biochemistry
- Pharmacology
Background:
- Labile plasma iron (LPI) is a redox-active, chelatable component of non-transferrin-bound iron (NTBI).
- LPI contributes to organ iron overload in conditions like hemosiderosis and thalassemia.
- Sustained LPI levels can impair organ function and reduce patient survival.
Purpose of the Study:
- To review iron chelation regimens for their efficacy in minimizing LPI exposure.
- To assess the clinical implications of measuring LPI in iron overload management.
- To evaluate deferrioxamine and deferiprone in reducing LPI in thalassemia patients.
Main Methods:
- Review of iron chelation regimens including deferrioxamine and deferiprone (alone or combined).
- Focus on minimizing daily exposure to labile plasma iron (LPI).
- Assessment in patients with thalassemia major and thalassemia intermedia.
Main Results:
- Iron chelation therapy can reduce daily exposure to labile plasma iron (LPI).
- Specific regimens show varying efficacy in LPI reduction.
- LPI measurement aids in managing iron overload.
Conclusions:
- Iron chelation is crucial for managing LPI in thalassemia.
- Therapeutic strategies aim to minimize LPI exposure and mitigate organ damage.
- Further research on LPI's role in iron overload is warranted.